Ranibizumab doesn’t reduce rate of new onset CNV in untreated fellow eyes

Researchers retrospectively reviewed data from the MARINA and ANCHOR studies to determine the effect of monthly ranibizumab injections on the untreated fellow eyes of patients with unilateral neovascular AMD. At two years, choroidal neovascularization (CNV) developed in fellow eyes at a rate of 30.4 percent (0.3-mg group) and 38.0 percent (0.5-mg) in MARINA and in 23.8 percent (0.3-mg group) and 35.1 percent (0.5-mg) in ANCHOR.  These conversion rates were substantially higher than previous reports looking at similar patient populations.